Tau RNA interference (tauRNAi) provides an avenue across (trans) potential biological barriers by incorporating our proprietary and highly effective DiLA2 liposome and UsiRNA construct technologies into a single platform for RNAi. By merging the two technologies, Marina is able to tailor both UsiRNA construct and DiLA2 liposome characteristics to target specific tissues and diseases resulting from overexpression of proteins in those tissues. Maximal therapeutic effect can result from optimization of the UsiRNA through strategic placement of UNAs and CRNs to provide stability to nucleases, mitigate a cytokine response, and reduce off-target effects, while maintaining exceptional activity against the intended target. Appropriate choice of the DiLA2 molecule enables the optimization of charge, size, and other characteristics of the liposome for delivery to a particular tissue or tumor type. Further improvements can arise from the selection of liposome components as well as the manufacturing processes for the drug product.